Skip to main content

Global Genomics Market Size [2022-2028] to Reach USD 94.66 Billion, with stunning 19.4% CAGR

Key Players Covered in the Genomics Market Research Report are Illumina, Inc. (California, U.S.), Thermo Fisher Scientific Inc. (Massachusetts, United States), Pacific Biosciences of California, Inc. (California, U.S.), F. Hoffmann-La Roche Ltd. (Basel, Switzerland), Agilent Technologies, Inc. (California, U.S.), Oxford Nanopore Technologies (England, U.K.), Danaher (Washington, D.C., U.S.), QIAGEN (Hilden, Germany), BGI (Guangdong, China), IntegraGen (Evry, France), General Electric Company (Illinois, U.S.) and other key market players

Pune, India, Feb. 02, 2022 (GLOBE NEWSWIRE) — The global genomics market size is projected to reach USD 94.66 billion by 2028, exhibiting a CAGR of 19.4% during the forecast period. Fortune Business Insights™ shares this information in its report, titled “Genomics Market, 2021-2028”. As per the report, the value of the market stood at USD 23.12 billion in 2020 and USD 27.81 billion in 2021. One of the key factors promoting the significance of this field of biology is its potential to manage zoonotic diseases, such as rabies, bird flu, plague, and the evident coronavirus. These diseases are life-threatening and can cause huge burdens if not monitored carefully. According to the World Health Organization, in 2020, rabies accounted for nearly 55 000 deaths in Asia and Africa.

Industry Developments:

August 2020 – Ancestry, a privately-held genealogy company launched AncestryHealth, which comprises next-generation sequencing and screening capabilities of genes associated with diseases such as colon cancer, breast cancer, blood disorders, and heart diseases. 


Request a Sample Copy of the Research Report: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/genomics-market-100941


Report Scope & Segmentation

Report Coverage Details
Forecast Period 2021 to 2028
Forecast Period 2021 to 2028 CAGR 19.4%
2028 Value Projection USD 94.66 Billion
Base Year 2020
Market Size in 2020 USD 27.81 Billion
Historical Data for 2017 to 2019
No. of Pages 160
Segments covered Type, Technology, Application, End-User and Geography
Growth Drivers Rising number of Government Genome Project to Drive the Market
New Products and Innovative Services to Favor the adoption of sequencing
Increasing Research Funding by Government to Surge the Research Institutes Segments


Increasing Government Funded Products Supporting Genomics to Drive Growth

Governments worldwide are focusing on developing the healthcare infrastructure of their countries by investing in research facilities and other advancing domains in the industry. Genomics has been the key area of investments since the study helps scientists and medical professionals understand diseases and develop an effective cure for the same. The increasing number of government-funded projects in the field of such studies is projected to drive the genomics market growth. For instance, in January 2020, Genomics England, a specialized enterprise operated by the Department of Health and Social Care in the U.K., partnered with Illumina to develop nearly three lakh genome equivalents in the span of five years.


Click here to get the short-term and long-term impact of COVID-19 on this market.

Please visit: https://www.fortunebusinessinsights.com/industry-reports/genomics-market-100941


Genomic sequencing to Showcase High Demand amid COVID-19 Due to Rising Application

Genomic sequencing has played a vital role in identifying and diagnosing the COVID-19 virus. Continuous sequencing during the pandemic has enabled healthcare experts to closely monitor the virus, which has helped in developing effective vaccines. Such episodes have propelled the demand for genomics. Based on our findings, the genomics market experienced robust growth of 22.6% in 2020.

Surging Adoption of Third-generation Sequencing to Boost Demand in North America

The market value of North America stood at USD 10.16 billion in 2020. The increasing adoption of the latest generation of sequencing is predicted to strengthen the genomics market share in the region. Another factor boosting growth is the presence of best-in-class healthcare infrastructure in the U.S. In addition, the growing inclination toward personalized therapy and treatment of diseases is anticipated to propel the demand for genomics in the region.  

The rapidly surging demand for genetic sequencing and testing in China and advancements in bioinformatics in the region are some of the key factors driving the genomics market in Asia Pacific. In addition, the high interaction of people with livestock in India and China increases the risk of animal-based zoonotic diseases, further strengthening the demand for genomics in the region.


Quick Buy Genomics Market Research Report: https://www.fortunebusinessinsights.com/checkout-page/100941


Developing Advanced Facilities to Help Key Players Offer Personalized Medicines

Prominent enterprises operating in the market are focusing on leveraging the third generation of sequencing in order to explore new horizons in the field. Such technological advancements will help them offer personalized medicines. Industry leaders are investing in establishing cutting-edge facilities to develop their services. For instance, in October 2018, Helix OpCo LLC, a leading enterprise specialized in genomics study, established a new DNA Product Studio in San Carlos, California. This new facility will help the company develop new applications and tests.


Key Players in the Global Genomics Market:

  • Illumina Inc. (California, U.S.)
  • Thermo Fisher Scientific Inc. (Massachusetts, U.S.)
  • Pacific biosciences of California Inc. (California, U.S.)
  • F. Hoffman-La Roche Ltd. (Basel, Switzerland)
  • Agilent Technologies Inc. (California, U.S.)
  • Oxford Nanopore Technologies (England, U.K.)
  • Danaher (Washington, D.C., U.S.)
  • QIAGEN (Hilden, Germany)
  • BGI (Guangdong, China)
  • IntegraGen (Evry, France)
  • General Electric Company (Illinois, U.S.)
  • Bio-Rad Laboratories (Illinois, U.S.)


Have Any Query? Ask Our Experts: https://www.fortunebusinessinsights.com/checkout-page/100941


About Us:

Fortune Business Insights™ delivers accurate data and innovative corporate analysis, helping organizations of all sizes make appropriate decisions. We tailor novel solutions for our clients, assisting them to address various challenges distinct to their businesses. Our aim is to empower them with holistic market intelligence, providing a granular overview of the market they are operating in.

Contact Us:

US :+1 424 253 0390

UK : +44 2071 939123

APAC : +91 744 740 1245

Email: sales@fortunebusinessinsights.com

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Important Notice for Investors:

The services and products offered by Goldalea Capital Ltd. are intended exclusively for professional market participants as defined by applicable laws and regulations. This typically includes institutional investors, qualified investors, and high-net-worth individuals who have sufficient knowledge, experience, resources, and independence to assess the risks of trading on their own.

No Investment Advice:

The information, analyses, and market data provided are for general information purposes only and do not constitute individual investment advice. They should not be construed as a basis for investment decisions and do not take into account the specific investment objectives, financial situation, or individual needs of any recipient.

High Risks:

Trading in financial instruments is associated with significant risks and may result in the complete loss of the invested capital. Goldalea Capital Ltd. accepts no liability for losses incurred as a result of the use of the information provided or the execution of transactions.

Sole Responsibility:

The decision to invest or not to invest is solely the responsibility of the investor. Investors should obtain comprehensive information about the risks involved before making any investment decision and, if necessary, seek independent advice.

No Guarantees:

Goldalea Capital Ltd. makes no warranties or representations as to the accuracy, completeness, or timeliness of the information provided. Markets are subject to constant change, and past performance is not a reliable indicator of future results.

Regional Restrictions:

The services offered by Goldalea Capital Ltd. may not be available to all persons or in all countries. It is the responsibility of the investor to ensure that they are authorized to use the services offered.

Please note: This disclaimer is for general information purposes only and does not replace individual legal or tax advice.